Medizinische Klinik und Poliklinik IVKlinikum der Universität München, Ziemssenstraße 1, D-80336 Munich, GermanyDepartment of NeurosurgeryUniversity of Tuebingen, Tuebingen, GermanyInstitut für klinische RadiologieKlinikum der Ludwig-Maximilians-Universität München, Munich, Germany.
Medizinische Klinik und Poliklinik IVKlinikum der Universität München, Ziemssenstraße 1, D-80336 Munich, GermanyDepartment of NeurosurgeryUniversity of Tuebingen, Tuebingen, GermanyInstitut für klinische RadiologieKlinikum der Ludwig-Maximilians-Universität München, Munich, Germany
Eur J Endocrinol. 2015 Aug;173(2):197-204. doi: 10.1530/EJE-14-0912. Epub 2015 May 7.
The aim of the present study was to validate criteria of corticotropin-releasing hormone (CRH) stimulation and 8 mg dexamethasone suppression (high-dose dexamethasone suppression, HDDS) to distinguish the etiology of ACTH-dependent Cushing's syndrome.
We retrospectively analyzed cortisol and ACTH after the injection of 100 μg human CRH in confirmed Cushing's disease (CD, n=78) and confirmed ectopic Cushing's syndrome (ECS, n=18). Cortisol and ACTH increase (in percentage above basal (%B)) at each time point, maximal increase (Δmax %B), and area under the curve (AUC %B) were analyzed using receiver operator characteristics (ROC) curve analyses. Cortisol suppression (%B) after 8 mg of dexamethasone was evaluated as a supplementary criterion.
An increase in ACTH of ≥ 43%B at 15 min after CRH was the strongest predictor of CD, with a positive likelihood ratio of 14.0, a sensitivity of 83%, a specificity of 94%, a positive predictive value of 98% and a negative predictive value of 58%. All of the other criteria of stimulated ACTH and cortisol levels were not superior in predicting CD in response to CRH injection. The addition of cortisol suppression by dexamethasone did not increase the discriminatory power. However, the combination of a positive ACTH response at 15 min and a positive HDDS test excluded ECS in all cases.
The present findings support the use of plasma ACTH levels 15 min after the injection of human CRH as a response criterion for distinguishing between CD and ECS. The addition of the HDDS test is helpful for excluding ECS when both tests are positive.
本研究旨在验证促肾上腺皮质激素释放激素(CRH)刺激和 8mg 地塞米松抑制(高剂量地塞米松抑制,HDDS)标准,以区分 ACTH 依赖性库欣综合征的病因。
我们回顾性分析了确诊库欣病(CD,n=78)和异位库欣综合征(ECS,n=18)患者注射 100μg 人 CRH 后皮质醇和 ACTH 的变化。使用受试者工作特征(ROC)曲线分析每个时间点的皮质醇和 ACTH 增加量(相对于基础值的百分比,%B)、最大增加量(Δmax %B)和曲线下面积(AUC %B)。评估 8mg 地塞米松抑制后皮质醇抑制(%B)作为补充标准。
CRH 后 15 分钟 ACTH 增加≥43%B 是 CD 的最强预测因子,阳性似然比为 14.0,敏感性为 83%,特异性为 94%,阳性预测值为 98%,阴性预测值为 58%。其他刺激后 ACTH 和皮质醇水平的标准在预测 CRH 注射反应中的 CD 方面均不优越。地塞米松抑制的添加并没有增加鉴别力。然而,在所有情况下,15 分钟时 ACTH 反应阳性和 HDDS 试验阳性的组合都排除了 ECS。
本研究结果支持使用注射人 CRH 后 15 分钟时的血浆 ACTH 水平作为区分 CD 和 ECS 的反应标准。当两项测试均为阳性时,添加 HDDS 测试有助于排除 ECS。